1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Nanologica AB

Nanologica AB

SSTO:NICA
0.25
SEK
+0.00
(-1.96%)
159.12MMarket Cap
Nov 26Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.85
1.32
0.5
0.53
0.34
0.53
0.64
0.44
0.05
0.04
0.29
0.24
- -
Basic EPS, GAAP
-7.59
-5.77
-5.64
-4.12
-1.7
-1.2
-0.88
-1.52
-1.74
-1.97
-1.31
-0.58
- -
Free Cash Flow per Basic Share
- -
-7.8
-6.45
-5.15
-1.2
-2.31
-1.98
-1.82
-1.7
-1.49
-1.63
-0.46
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.26
5.9
4.36
0.38
1.51
0.31
3.17
1.74
1.92
-0.05
0.83
0.25
0.48
Tangible Book Value per Share
0.4
3.68
2.88
-0.87
1.15
-0.41
2.7
1.26
1.5
-0.66
0.66
0.15
0.45
Basic Weighted Avg Shares
2
2
4
5
12
18
25
30
32
38
50
89
141
Sales/Revenue/Turnover
2
3
2
3
4
9
16
13
2
1
15
21
- -
Operating Margin (%)
-880.4
-429.42
-1,100.91
-742.14
-513.75
-221.65
-124.6
-302.24
-3,224.24
-3,812.4
-329.58
-233.74
- -
Depreciation Expense
2
3
3
3
3
4
6
10
12
14
14
12
- -
Net Income, GAAP
-15
-14
-22
-20
-21
-21
-22
-45
-55
-75
-66
-51
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-894.9
-438.02
-1,122.76
-772.94
-503.92
-228.46
-137.58
-347.13
-3,551.83
-5,208.39
-451.43
-242.77
- -
Working Capital
3
16
17
-3
19
-7
83
42
103
27
45
31
81
LT Debt
- -
1
4
3
10
13
8
5
1
- -
- -
- -
43
Total Equity
8
24
22
2
26
5
93
52
73
-2
74
23
156
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-88.49
-97.29
-167.66
-146.95
-132.16
-45.13
-62.02
-88.54
- -
- -
-106.02
- -

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
21
74
10
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
45
43
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
89
121
329
Market Capitalization
69
47
159

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
68
137
125
Cash, Cash Equivalents & STI
4
39
19
Accounts Receivable, Net
4
12
19
Inventories
28
41
55
Total Current Liabilities
37
119
44
Payables & Accruals
- -
- -
- -
ST Debt
21
74
10
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-147.39%
-835.9%
-69.44%
Free Cash Flow
19.55%
1.42%
-49.78%
Net Income, GAAP
18.35%
25.34%
-21.85%
Sales/Revenue/Turnover
108.59%
167.54%
45.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
2
1
7
15
2025
11
2
- -
5
21
2026
21
24
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.45
-0.24
-0.53
-0.19
-1.31
2025
-0.14
-0.15
- -
-0.19
-0.58
2026
0.72
-0.06
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Andreas Bhagwani
Full Time Employees
19
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Forskargatan 20 G Södertälje AB Sweden 151 36
IPO Date
Oct 30, 2015
Website
nanologica.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Nanologica AB (publ) is a Swedish nanotechnology company that develops, manufactures and sells nanoporous silica particles and related consumables for purification by preparative chromatography to pharmaceutical manufacturers worldwide. The company offers NLAB Saga, a silica-based purification media specially designed for peptide drugs including insulin and GLP-1 analogues such as Ozempic and Wegovy; SVEA, pre-packed columns for analytical chromatography; and complementary non-silica-based purification media; with operations spanning sales directly and via partners in China, India, the US and Europe, supported by large-scale production at contract manufacturers in the UK and Ireland. Founded in 2004 and headquartered in Södertälje, Sweden, Nanologica targets the growing market for diabetes and obesity treatments by enabling cost reductions and higher productivity in drug production. Recent developments include multiple orders in 2025 for NLAB Saga from customers in China and the US, such as a SEK 1.9 million repeat order from a Chinese GLP-1 producer in late 2024, a SEK 2.7 million supplementary order from a US peptide manufacturer in October 2025, a SEK 1 million sampling order via a new Chinese distributor in October 2025 and entry into China's insulin market with a SEK 2 million order in early October 2025; alongside a completed rights issue in late 2024 raising SEK 76.5 million net proceeds and repayment of bridge financing.